UNSPSC 51293013: Amitriptyline pamoate

This classification denotes a tricyclic antidepressant with the molecular formula C23H16O6.2C20H23N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YX6VNM127F. Most nations, for tariff and trade purposes, schedule amitriptyline pamoate under HS 29214980 and SITC 51454. As of Q4 2014, AMITRIPTYLINE PAMOATE remains US FDA's Preferred Term for this commodity. Amitriptyline pamoate bears US NLM identifiers UMLS ID C0770882 and NCI Concept Code C96201.

SMILES: CN(C)CCC=C1C2CCCCC2CCC3C1CCCC3.CN(C)CCC=C1C2CCCCC2CCC3C1CCCC3.C1CCC2C(C1)CC(C(C2CC3C4CCCCC4CC(C3O)C(=O)O)O)C(=O)O.

UNSPSC 51293013 Amitriptyline pamoate is a Commodity code that nominally identifies a single pharmaceutical product, yet the recent state and local opportunities posted under this code show minimal direct procurement of amitriptyline pamoate itself. Instead, the opportunities reflect broader pharmaceutical supply and emergency-response procurement by state health agencies, county health departments, and cooperative purchasing alliances. State and local governments use this code tier and related pharmaceutical codes to solicit generic multi-source drugs, naloxone and drug deactivation systems, and direct-to-manufacturer prescription programs that support public health initiatives, emergency response, and cost-effective pharmacy benefit management across multiple jurisdictions and facility types.

Recent solicitation activity spans Texas, Minnesota (with participating states including Oregon), and Florida. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program that would establish direct relationships between the state's pharmacy benefit program and pharmaceutical manufacturers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted RFP S1070000015802 on January 20, 2026, with a response deadline of March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across state and local government facilities; awarded vendors must maintain relationships with at least two of three authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act requirements, with price competitiveness weighted at 75 percent of the evaluation. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, to procure 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through quarterly deliveries, with a response deadline of July 26, 2026. These opportunities indicate that pharmaceutical commodity codes at this tier are actively used by state health departments and counties to procure emergency-response medications, generic drugs, and pharmacy services rather than single-drug line items.